Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

Short summary

Ranibizumab injections sustained visual acuity gains and reduced retinal thickness in diabetic macular edema (DME) patients through 36 months, with 36.8%-40.2% (0.3 mg) and 40.2%-51.2% (0.5 mg) gaining ≥15 letters at 36 months.

AI-generated from the title and abstract; the full text is not read.